(4893) Stock Price

Noil Immune Biotech's primary business is developing cancer immunotherapy. The company focuses particularly on developing CAR-T cell therapy for solid tumors, leveraging its proprietary PRIME technology. This technology aims to activate immune cells that attack cancer cells and enhance cancer treatment effectiveness.

Noil Immune Biotech operates a hybrid business model with two revenue streams: in-house drug development and collaborative pipelines. In in-house drug development, the company leads development directly. In collaborative pipelines, the company licenses its PRIME technology to other companies for drug development. This model accelerates market deployment of the technology and aims to secure early revenue.

The company's PRIME technology uses genetically modified CAR-T cells that produce cytokines and chemokines to promote immune cell activation and accumulation. This technology is expected to enhance treatment effectiveness against solid tumors. Additionally, PRIME technology is applicable to other immunotherapies and gene therapies, with potential expansion into a broad range of regenerative medicine fields.

Noil Immune Biotech operates in a single business segment focused on cancer immunotherapy, with no segment-specific information disclosed. The company advances technology development through collaborative research with domestic and international companies and research institutions, and pursues a licensing business leveraging intellectual property rights. This approach aims to generate revenue through technology access fees and royalties.

Noil Immune Biotech aims to create a future where cancer is overcome by focusing on the development of cancer treatments utilizing its innovative PRIME technology. This technology is designed to activate immune cells that attack cancer cells and enhance therapeutic efficacy. The company is particularly advancing next-generation cell therapy for solid tumors and seeking to establish its presence in the cancer immunotherapy field.

The company employs a hybrid business strategy combining two models: in-house drug discovery and collaborative pipelines. In in-house drug discovery, Noil Immune Biotech leads development directly. In collaborative pipelines, the company licenses its PRIME technology to other companies to advance pharmaceutical development. This model accelerates market deployment of the technology and aims to secure revenue early.

PRIME technology utilizes CAR-T cells that have been genetically modified to produce cytokines and chemokines that promote immune cell activation and accumulation. This technology is expected to enhance therapeutic efficacy against solid tumors. Additionally, the technology is applicable to other immunotherapies and gene therapies, with broad deployment anticipated across the regenerative medicine field.

Noil Immune Biotech advances technology development through collaborative research with domestic and international companies and research institutions, and operates a licensing business leveraging intellectual property rights. Through this approach, the company aims to generate revenue from technology access fees and royalties. The company is also establishing systems to accelerate research and development and expand its pipeline to achieve sustainable growth.